Page 2 - S Relapse News Today

Although serum glial fibrillary acid protein (GFAP) could be a useful complement to the multiple sclerosis biomarker neurofilament light chain (NfL), it is not ready for the clinic, experts say.

Two studies report few complications from continuing ocrelizumab and natalizumab into pregnancy, with high live birth rates, a decline in elective abortions, and few major congenital abnormalities in newborns.

Lower cardiorespiratory fitness predicts increased variability in stride time in people with MS and may serve as a biomarker of function decline.

Autologous hematopoietic stem cell transplantation is linked to significantly lower relapse rates than fingolimod in patients with relapsing-remitting multiple sclerosis. But adverse events are common.

Former employee/whistleblower to receive $250 million as part of settlement involving three drugs used to treat muscular sclerosis.

Ublituximab is superior to teriflunomide in suppressing multiple sclerosis relapses and lesions on MRI, suggest findings from the phase 3 ULTIMATE I and II trials.

The second-generation selective DHODH inhibitor vidofludimus calcium met a phase 2 trial primary endpoint of suppressing new active lesions on MRI and was well tolerated.

The first randomized trial to examine if older adults with multiple sclerosis can discontinue disease-modifying therapy after years of being relapse-free failed to deliver a definitive conclusion.

The novel anti-CD20 monoclonal antibody ublituximab showed greater improvement vs terifulnomide in stabilizing disease progression in relapsing multiple sclerosis in two phase 3 trials.

The investigational evobrutinib, an Brutons tyrosine kinase inhibitor, showed favorable safety and efficacy in the longest trial to date of a drug in this class in patients with multiple sclerosis.